DBV-135 is under clinical development by DBV Technologies and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DBV-135’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DBV-135 overview
DBV-135 is under development for the treatment of Cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis. The drug candidate is administered as an epicutaneous patch. The drug candidate is developed based on Viaskin patch delivery technology.
DBV Technologies overview
DBV Technologies is a biopharmaceutical company. It develops self-administered and non-invasive therapies to treat food allergies and other immunological diseases. Its product pipeline includes Viaskin peanut, Viaskin milk and Viaskin EoE indicated for the treatment of related food allergies in children. It offers clinical trial services which comprises food allergy clinical trials, milk clinical trials, egg pre clinical studies and peanut clinical trials. It markets its products under the brand such as Viaskin. DBV Technologies seeks to collaborate with institutes, universities and other pharmaceutical companies for the development and commercialization of its product candidates. It has operations in the US and France. DBV Technologies is headquartered in Paris, Ile-de-France, France.
For a complete picture of DBV-135’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
